2025Idorsia Ltd (SIX: IDIA) today announced that the hearing by the higher cantonal composition authority (obere kantonale Nachlassbehörde) (the Court) in relation to its outstanding convertible bond (ISIN: CH0426820350) (the Bonds or CB 2025) with a nominal value of CHF 200 million and a conversion price of CHF 6.00 per Idorsia share was held yesterday and that the Court approved the amendments of the Bond terms decided at the bondholder meeting held on February 25 The amended terms will become effective, if no appeal is filed against the court decision, within 30 days from the official publication of the written statement of the grounds. All information related to the meeting can be found at the following link: www.idorsia.com/CB2025 Approving this extension of the maturity of the CB 2025 until September 17, 2025 is the first step in a larger holistic restructuring to provide the time required for its implementation, as announced in a press release on February 26 the company will provide an update on the implementation of the holistic restructuring including the timing of the new money facility subscription process and exchange offer About IdorsiaIdorsia Ltd is reaching out for more – we have more passion for science The purpose of Idorsia is to challenge accepted medical paradigms and commercialize transformative medicines – either with in-house capabilities or together with partners – and evolve Idorsia into a leading biopharmaceutical company Switzerland – a European biotech hub – Idorsia has a highly experienced team of dedicated professionals covering all disciplines from bench to bedside; QUVIVIQ™ (daridorexant) a different kind of insomnia treatment with the potential to revolutionize this mounting public health concern; strong partners to maximize the value of our portfolio; a promising in-house development pipeline; and a specialized drug discovery engine focused on small-molecule drugs that can change the treatment paradigm for many patients Idorsia is listed on the SIX Swiss Exchange (ticker symbol: IDIA) please contact:Investor & Media RelationsIdorsia Pharmaceuticals Ltd CH-4123 Allschwil+41 58 844 10 10investor.relations@idorsia.com – media.relations@idorsia.com – www.idorsia.com The above information contains certain "forward-looking statements" which can be identified by the use of forward-looking terminology such as "estimates" "pending" or "anticipates" or similar expressions Such statements include descriptions of the company's investment and research and development programs and anticipated expenditures in connection therewith descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company's existing portfolio Such statements reflect the current views of the company with respect to future events and are subject to certain risks Many factors could cause the actual results performance or achievements of the company to be materially different from any future results performances or achievements that may be expressed or implied by such forward-looking statements Should one or more of these risks or uncertainties materialize or should underlying assumptions prove incorrect actual results may vary materially from those described herein as anticipated a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections reported today that the sales of the antifungal Cresemba® (isavuconazole) in Japan exceeded the threshold triggering the first sales milestone payment from its partner Asahi Kasei Pharma (AKP) amounting to approximately CHF 1.2 million said: “Japan is a key market with significant growth potential for Cresemba The achievement of the first sales milestone already in the second year of commercialization is a testament of the commercial capability of our partner AKP in this important market The strong sales ramp-up in the early stage of its life cycle in Japan underscores that Cresemba is meeting critical medical needs of patients with life-threatening fungal infections.” Cresemba was marketed in more than 70 countries According to the latest available market data total global in-market sales of Cresemba in the twelve-month period between October 2023 and September 2024 amounted to USD 533 million making it the largest branded antifungal for invasive fungal infections worldwide.1 Isavuconazole is an intravenous (i.v.) and oral azole antifungal commercialized under the trade name Cresemba the oral and intravenous formulations are approved for the treatment of adult patients with aspergillosis and cryptococcosis.2 Isavuconazole is also approved in the United States (US),3 China the EU4 and several additional countries in Europe and beyond.5 Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland developing and commercializing innovative drugs to meet the needs of patients with severe bacterial and fungal infections We have successfully launched two hospital brands Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of bacterial infections we have preclinical and clinical anti-infective assets in our portfolio Basilea is listed on the SIX Swiss Exchange (SIX: BSLN) This communication expressly or implicitly contains certain forward-looking statements "will" or similar expressions concerning Basilea Pharmaceutica Ltd development and clinical studies for product candidates Such statements involve certain known and unknown risks performance or achievements of Basilea Pharmaceutica Ltd Allschwil to be materially different from any future results performance or achievements expressed or implied by such forward-looking statements Allschwil is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information This press release can be downloaded from www.basilea.com The site you’re being redirected to is a branded pharmaceutical website Please click below to continue to that site Supporting innovation in Switzerland is a matter close to Johnson & Johnson’s heart That is why the Johnson & Johnson (J&J) Innovation Hub Switzerland was recently opened at the Basel/Allschwil site Situated within our J&J offices in Basel the Hub will further support our Innovation team in fostering connections with external collaborators from the abundant innovation ecosystem in Switzerland Johnson & Johnson Innovation’s mission is to find the best early-stage innovations that could transform health outcomes for patients The team prides itself on being able to spot and nurture the right opportunities at the right times and over the last 10 years (2014-2023) have invested over $1.7 Billion in collaborations* in the EMEA region Their approach is to work hand in hand with researchers and company founders with biotech and medtech innovations at an early stage supporting them every step of the way and providing a unique perspective through expertise across both Innovative Medicine and Medtech The team also understand the uniqueness of each partnership and can personalize support to include: collaboration and deal making; incubation and acceleration through J&J Innovation – JLABS; and equity investment through J&J Innovation JJDC collaborators can access expertise from across J&J and our network J&J Innovation is a part of the BaseLaunch Healthcare Accelerator which provides support to Swiss start-ups and prepares them for partnerships with pharmaceutical and venture capital companies JLABS @ EMEA also welcomed two Swiss start-ups one working on cell therapies against cancer and the other a virtual reality solution for planning surgical interventions.” * through our London Innovation Centre and Johnson & Johnson Innovation – JJDC Inc This site is aimed at users from Switzerland. Use of this site constitutes your consent to application of such laws and regulations and to our Privacy Policy. Your use of the information on this site is subject to the terms of our Terms of Use All contents © Copyright Cilag GmbH International.All Rights Reserved announced today that sales of the antifungal Cresemba® (isavuconazole) by its license partner Pfizer in Europe exceeded the threshold that triggered a milestone payment of USD 25 million to Basilea said: “We are very pleased with the continued recognition of Cresemba in meeting the critical medical needs of patients with life-threatening invasive mold infections and its strong sales performance in Europe which has resulted in this milestone payment We already announced several sales milestone payments from sales in Asia Pacific and China this year The number of sales milestone payments triggered this year reflect Cresemba’s ongoing success and sustained growth around the world.” The license agreement between Basilea and Pfizer for Cresemba covers Europe (excluding the Nordic countries) as well as 16 countries in the Asia Pacific region and China Cresemba is approved and marketed in more than 70 countries most EU member states and additional countries inside and outside of Europe total global in-market sales of Cresemba amounted to USD 489 million in the 12 months between April 2023 and March 2024 commercialized under the trade name Cresemba® Basilea has entered into several license and distribution agreements for isavuconazole covering approximately 115 countries isavuconazole is approved for patients aged from 1 year of age and older for the treatment of invasive aspergillosis and for the treatment of mucormycosis in patients for whom amphotericin B is inappropriate.2 Isavuconazole is also approved in the United States (US) and several additional countries in Europe and beyond China and Japan.3 It has orphan drug designation in the US Europe and Australia for its approved indications This ad hoc announcement can be downloaded from www.basilea.com ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel die an schweren Infektionen durch Bakterien oder Pilze erkrankt sind dass die Aktionärinnen und Aktionäre an der heutigen ordentlichen Generalversammlung (GV) für das Geschäftsjahr 2024 allen vom Verwaltungsrat vorgeschlagenen Anträgen zugestimmt haben An der GV genehmigten die Aktionäre den Lagebericht die Jahresrechnung und die Konzernrechnung für das Geschäftsjahr 2024 Sie stimmten ausserdem dem Vortrag des Bilanzverlusts auf neue Rechnung zu und entlasteten die Mitglieder des Verwaltungsrats sowie der Geschäftsleitung Stephan Schindler wurde zum neuen Präsidenten des Verwaltungsrats gewählt Thomas Werner als Mitglieder des Verwaltungsrats wiedergewählt wurden Zudem wurde Leonard Kruimer neu in den Vergütungsausschuss gewählt und Dr Onetto als Mitglieder des Vergütungsausschusses wiedergewählt Die Amtsdauer aller Verwaltungsräte endet mit dem Abschluss der GV 2026 Ausserdem genehmigten die Aktionärinnen und Aktionäre den vorgeschlagenen maximalen Gesamtbetrag der Vergütung des Verwaltungsrats für den Zeitraum von der GV 2025 bis zur GV 2026 und den maximalen Gesamtbetrag der Vergütung (fixe und variable Vergütung) der Geschäftsleitung für das Geschäftsjahr 2026 Im Rahmen einer nicht-bindenden Konsultativabstimmung hiessen die Aktionärinnen und Aktionäre auch den Vergütungsbericht für das Geschäftsjahr 2024 gut Caroline Cron von den Aktionärinnen und Aktionären als unabhängige Stimmrechtsvertreterin mit einer Amtsdauer bis zum Abschluss der nächsten GV wiedergewählt und Ernst & Young AG als Revisionsstelle für das Geschäftsjahr 2025 gewählt Domenico Scala sagte: «Ich möchte unseren Aktionären für ihre deutliche Unterstützung der vom Verwaltungsrat vorgeschlagenen Anträge danken Insbesondere gratuliere ich Stephan Schindler zu seiner Wahl zum neuen Verwaltungsratspräsidenten Nachdem ich dem Verwaltungsrat seit 2011 angehört habe davon die letzten neun Jahre als Präsident und Basilea sich in einer starken Position befindet den Staffelstab an Stephan Schindler weitergeben zu können Er ist eine erfahrene Führungspersönlichkeit im Life-Sciences-Bereich und ich bin zuversichtlich An der GV waren 31.9 % des Aktienkapitals vertreten Insgesamt sind derzeit 66.6 % des Aktienkapitals im Aktienregister der Basilea eingetragen Diese Mitteilung enthält explizit oder implizit gewisse zukunftsgerichtete Aussagen wie «glauben» «werden» oder ähnliche Ausdrücke betreffend Basilea Pharmaceutica AG den Zeitplan und den Abschluss von Forschung und Entwicklung sowie klinischer Studien mit Produktkandidaten Solche Aussagen beinhalten bekannte und unbekannte Risiken und Unsicherheitsfaktoren die Leistungen oder Errungenschaften der Basilea Pharmaceutica AG Allschwil wesentlich von denjenigen Angaben abweichen können die aus den zukunftsgerichteten Aussagen hervorgehen Diese Mitteilung ist mit dem heutigen Datum versehen Allschwil übernimmt keinerlei Verpflichtung zukunftsgerichtete Aussagen im Falle von neuen Informationen zukünftigen Geschehnissen oder aus sonstigen Gründen zu aktualisieren Für weitere Informationen kontaktieren Sie bitte: Diese Pressemitteilung ist unter www.basilea.com abrufbar reported that shareholders approved all proposals of the board of directors at today’s annual general meeting (AGM) for the financial year 2024 the shareholders approved the annual report the financial statements and the consolidated financial statements for the financial year 2024 They also endorsed carrying forward the accumulated deficit and approved the discharge of the members of the board of directors and the management committee Stephan Schindler was elected as chairman and Mr Thomas Werner were re-elected as members of the board of directors Onetto were re-elected to the compensation committee The term of all board members lasts until the AGM 2026 The shareholders also approved the proposed maximum aggregate amount of compensation for the board of directors for the period from the AGM 2025 to the AGM 2026 and the maximum aggregate amount of total compensation (fixed and variable) for the management committee for the financial year 2026 the shareholders endorsed the compensation report for the financial year 2024 Caroline Cron as independent proxy until the end of the next AGM and elected Ernst & Young Ltd Domenico Scala said: “I would like to thank our shareholders for their strong support of the motions proposed by the board of directors I congratulate Stephan Schindler on his election as the new chairman I am confident he will help guide Basilea to continued success.” equivalent to 56.1% of the shares entitled to vote 66.6% of the share capital is currently registered in Basilea’s share register This press release can be downloaded from www.basilea.com announced today scientific presentations on Basilea’s clinical-stage novel antifungal fosmanogepix given at ESCMID Global 2025 the annual meeting of the European Society of Clinical Microbiology and Infectious Diseases Further presentations covered the antifungal isavuconazole (Cresemba®) and the antibiotic ceftobiprole (Zevtera®) said: “Invasive fungal infections are an increasing global health problem and novel antifungals are urgently needed To date more than 250 patients suffering from difficult-to-treat invasive fungal infections have received fosmanogepix via expanded access The data presented at ESCMID highlight the potential of fosmanogepix as a life-saving treatment option in severe fungal infections based on the results from a large cohort of patients with invasive fusariosis as well as from patients with mucormycosis who received fosmanogepix via expanded access We look forward to the start of our second phase 3 study with fosmanogepix covering a broad range of mold infections More than 250 patients from 11 countries with serious or life-threatening invasive fungal infections who progressed on antifungal standard-of-care treatment or had infections with resistant fungal pathogens received fosmanogepix via expanded access to date (NCT06433128) treatment with fosmanogepix resulted in favorable response rates of 70% or higher in patients with invasive fusariosis or mucormycosis and it was tolerated for long treatment durations Further presentations reported on the activity of fosmanogepix against diverse yeast and mold species collected as part of a worldwide surveillance program Fosmanogepix is a clinical-stage broad-spectrum antifungal It has a novel mechanism of action and its active moiety has shown activity against common species of Candida and Aspergillus such as Candida auris and Candida glabrata as well as rare difficult-to-treat molds including Fusarium spp. and some fungi from the Mucorales order.1 Fosmanogepix intravenous and oral formulations have been evaluated in clinical phase 2 studies for the treatment of patients with Candidemia and invasive mold infections.1 A phase 3 study evaluating fosmanogepix in the treatment of adult patients with candidemia and/or invasive candidiasis is ongoing.2 Fosmanogepix has received Fast Track and Orphan Drug designations from the US Food and Drug Administration for seven separate indications and is designated as a Qualified Infectious Disease Product (QIDP) This project has been funded in part with federal funds from the U.S Department of Health and Human Services (HHS); Administration of Strategic Preparedness and Response (ASPR); Biomedical Advanced Research and Development Authority (BARDA) The contract and federal funding are not an endorsement of the study results is an intravenous (i.v.) and oral azole antifungal isavuconazole is approved for patients aged from 1 year of age and older for the treatment of invasive aspergillosis and for the treatment of mucormycosis in patients for whom amphotericin B is inappropriate.3 Isavuconazole is also approved in the United States (US)4 and several additional countries in Europe and beyond China and Japan.6 It has orphan drug designation in the US About Zevtera® (ceftobiprole medocaril sodium for injection) the active moiety of the prodrug ceftobiprole medocaril is an advanced generation cephalosporin antibiotic for intravenous administration with rapid bactericidal activity against a wide range of Gram-positive bacteria including methicillin-resistant strains (MRSA) and Gram-negative bacteria.7 In several countries in Europe and beyond the brand is currently approved and marketed as Zevtera® and Mabelio® for the treatment of adult patients with hospital-acquired bacterial pneumonia (HABP) excluding ventilator-associated bacterial pneumonia (VABP) and for the treatment of community-acquired bacterial pneumonia (CABP).7 In the United States ZEVTERA® is indicated for the treatment of adult patients with Staphylococcus aureus bloodstream infections (bacteremia) (SAB) including right-sided infective endocarditis and adult patients with acute bacterial skin and skin structure infections (ABSSSI) and for adult and pediatric patients (3 months to less than 18 years old) with community-acquired bacterial pneumonia (CABP).8 This press release can be downloaded from www.basilea.com Press release (PDF) 2024Idorsia Ltd (SIX: IDIA) today announced that it has entered into exclusive negotiations with an undisclosed party for the global rights to aprocitentan Idorsia will receive an exclusivity fee of USD 35 million which extends Idorsia’s cash runway into 2025 The potential agreement under discussion could include an upfront payment and tiered royalties on sales in return for the transfer of global rights to aprocitentan and certain team members from Idorsia commented: “I am pleased to announce that we made an important step to reaching a potential agreement for the global rights to aprocitentan We are targeting signing before the end of 2024 and closing in early 2025 more details will be shared should a final agreement be signed This is a first and crucial step in our plan to put Idorsia in a financially sustainable position and on the road towards profitability.” we are implementing initiatives which include cost-containment measures and steps to restructure our outstanding debt I am confident that our plan is achievable within the next few months and that will allow us to shift our focus back to our products we must contain our ambition and restrict our investments until we are generating the revenues from both proprietary and partnered products that will sustain our activities.” Planned company restructuringTo reach sustainable profitability reducing the number of active projects in research and development and preparing some for out-licensing a reduction of the number of employees is envisaged Depending on the outcome of a consultation process initiated with employee representatives at headquarters approximately 270 positions globally could become redundant mainly in Research & Development and support functions at headquarters Idorsia’s key global functions will continue to be headquartered in Allschwil The company is committed to minimizing the number of potential redundancies through natural attrition As part of the ongoing aprocitentan discussions the company is looking for ways to mitigate the social impact   The company expects some employees could potentially be offered the opportunity to continue to pursue their efforts to make aprocitentan a success should a final agreement be reached Upon completion of the consultation process Idorsia intends to conclude restructuring by the end of 2024 with the cost reduction becoming fully effective by Q2 2025 About aprocitentanAprocitentan is Idorsia’s once-daily which inhibits the binding of ET-1 to ETA and ETB receptors aprocitentan was approved as TRYVIO™ in the US aprocitentan was granted market authorization by the European Commission as JERAYGO™ and commercialize innovative medicines – either with in-house capabilities or together with partners – and evolve Idorsia into a leading biopharmaceutical company Switzerland – a European biotech hub – Idorsia has an experienced team of dedicated professionals For further information, please contactAndrew C. WeissSenior Vice President, Head of Investor Relations & Corporate CommunicationsIdorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil+41 (0)58 844 10 10investor.relations@idorsia.commedia.relations@idorsia.com www.idorsia.com The above information contains certain “forward-looking statements” which can be identified by the use of forward-looking terminology such as “estimates” “pending” or “anticipates” or similar expressions Such statements include descriptions of the company’s investment and research and development programs and anticipated expenditures in connection therewith descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company’s existing portfolio announced today its results for the financial year ended December 31 including the approval of Zevtera in the United States and the subsequent partnering with Innoviva Specialty Therapeutics for the commercialization of Zevtera in the US While Cresemba remains our most successful commercial brand we expect increasing growth contributions from Zevtera as the US represents 80-90% of its global commercial opportunity Zevtera is also making progress in existing markets as demonstrated by the achievement of the sales milestone in Europe in 2024 and by its inclusion in the National Reimbursement Drug List in China at the end of 2024 Cresemba gained approval in Europe for the use in children which not only makes the antifungal available for this vulnerable population but this also extended market exclusivity until October 2027.” we will focus on further advancing our portfolio first by starting the second phase 3 study with our potential next lead product we are continuing the preclinical work with the antifungal BAL2062 and the LptA inhibitor antibiotic in preparation for the subsequent clinical studies we have completed our pre-clinical profiling and taken the decision not to pursue further development This decision demonstrates that we are focused on stringent risk-return criteria when making portfolio decisions Another major achievement was the execution of a new BARDA-OTA contract providing us with reimbursement of up to USD 268 million which is 60% of the expected development costs for our clinical programs included in the OTA.“ said: “2024 has been an outstanding year for Basilea marking now our third year in a row of reporting a net profit and positive operating cash flows driven by the strong in-market sales of Cresemba which generated royalties of CHF 97 million which is an increase of more than 20% year-on-year We also reported milestone payments of almost CHF 40 million exceeding the already high levels in 2023 and including first sales milestones from Japan and the Middle East North Africa region for Cresemba We achieved a strong operating profit of CHF 61 million and reported a net profit of CHF 78 million We continue to generate significant positive cash flow and ended the year with CHF 125 million of cash cash equivalents and restricted cash and a net cash position of almost CHF 29 million we are in an excellent financial position to keep on progressing our R&D projects seizing in-licensing and acquisition opportunities to broaden our pipeline while strengthening our balance sheet in these times of increased volatility and macroeconomic uncertainty.” Basilea recognized total revenue of CHF 208.5m (FY 2023: CHF 157.6m) This included royalty income of CHF 96.7m (FY 2023: CHF 78.9m) from Cresemba and product revenue of CHF 57.8m (FY 2023: CHF 37.9m) Milestone and upfront payments increased to CHF 40.4m (FY 2023: CHF 33.5m) Other revenue amounted to CHF 13.7m (FY 2023: CHF 7.4m) This included CHF 10.2m BARDA reimbursements (FY 2023: CHF 4.2m) for remaining activities related to the phase 3 program for ceftobiprole and under the Other Transaction Agreement (OTA) executed in September 2024.1 Basilea invested CHF 77.1m (FY 2023: CHF 77.9m) in research and development mainly for the phase 3 program with fosmanogepix the preclinical profiling of BAL2062 and tonabacase the acquisition and preclinical activities for the LptA inhibitor program the remainder of the phase 3 ceftobiprole program and for research work on compounds in the Company’s early-stage portfolio including costs for the commercialization of Cresemba and Zevtera amounted to CHF 31.5m (FY 2023: CHF 33.8m) and cost of products sold increased to CHF 38.7m (FY 2023: CHF 26.8m) reflecting the significant increase in product revenue Basilea recorded an operating profit of CHF 61.2m (FY 2023: CHF 19.2m) As a consequence of its sustained profitability and its positive mid-term financial outlook the Company recognized deferred tax assets of CHF 17.3m which led to a net profit of CHF 77.6m (FY 2023: CHF 10.5m) resulting in basic and diluted earnings per share of CHF 6.42 and CHF 5.83 respectively (FY 2023: basic and diluted earnings per share CHF 0.87 and CHF 0.86 a positive net cash flow of CHF 74.4m was provided by operating activities (FY 2023: CHF 14.2m) The Company repaid the remaining CHF 15.6m of a CHF 75.0m senior secured loan by end of March 2024 Basilea shows a net cash position of CHF 28.6m as of December 31 Cash and cash equivalents and restricted cash amounted to CHF 124.6m as of December 31 Note: Consolidated figures in conformity with US GAAP; rounding was applied consistently The consolidated financial statements of Basilea Pharmaceutica Ltd, Allschwil for the financial year 2024 can be found on the company’s website at https://www.basilea.com/financial-reports 2025 Financial guidance – significantly growing royalty income and maintaining high operating profit while increasing R&D investments to advance pipeline Basilea provides the following guidance for the FY 2025: The board of directors has nominated Leonard Kruimer Thomas Werner for re-election as board members After serving on the board of directors for 14 years Domenico Scala has decided not to stand for re-election The board has nominated Stephan Schindler for election as a new board member and chairman said: “After having served on the board of directors since 2011 I decided to not seek re-election at the annual general meeting Basilea has made significant progress transforming into a focused organization and a leading anti-infectives company robust financials and a highly committed leadership team The company being in such a strong position I feel it is the right time to step down as board member and chairman.” The board of directors is proposing the nomination of Stephan Schindler as chairman of the board of directors He is a highly accomplished executive in the life science industry with over 30 years of experience across finance From 2009 to 2021 he was Chief Financial Officer of Bachem Holding AG he was head of Finance of DSM Nutritional Products and previously held various senior finance roles at Roche He is currently serving on the board of the University Children’s Hospital Basel as chairman of the board of Evolva Holding AG and as board member of Arcondis Holding AG Schindler was born and educated in Switzerland and holds Swiss citizenship Allschwil will host a conference call and webcast today to discuss the company’s financial and operating results and to provide an outlook The live audio webcast of the results presentation can be followed here: https://event.choruscall.com/mediaframe/webcast.html?webcastid=qyOSTJNH Please note that there is no function to ask questions via webcast please additionally dial-in via phone (see below) please call approximately 10-15 minutes prior to the scheduled start of the call The webcast, along with the presentation will be available online (same link as live audio webcast above) shortly after the event and accessible for three months This ad hoc announcement can be downloaded from www.basilea.com announced today that the continued strong sales performance of the antifungal Cresemba® (isavuconazole) by its license partner Pfizer Inc in the Asia Pacific region and China exceeded the sales threshold triggering a USD 2.5 million milestone payment stated: “We are pleased with the strong sales performance from our partner Pfizer resulting in this first sales milestone for the Asia Pacific and China region this year which significantly surpasses previous sales milestones for the region This underscores the continued progress in making Cresemba available to increasing numbers of patients suffering from life-threatening invasive mold infections in this region.” The license agreement between Basilea and Pfizer for Cresemba covers Europe (excluding the Nordic countries) as well as China and 16 countries in the Asia Pacific region Cresemba is marketed in more than 70 countries Basilea has entered into several license and distribution agreements for Cresemba covering approximately 115 countries the oral and intravenous formulations are approved for the treatment of adult patients with invasive aspergillosis and invasive mucormycosis Isavuconazole is also approved in the European Union2 the United States (US)4 and several additional countries including in the Asia Pacific region.5 This press release can be downloaded from www.basilea.com reported today on the progress of its Research & Development portfolio in 2024 and upcoming milestones said: “We have achieved several significant milestones in 2024 focused and capable company for the commercialization of our anti-MRSA antibiotic following its approval earlier in the year the European Commission expanded the approved uses to include treatment for pediatric patients This not only made Cresemba available to children but also extended its protection from generic competition in the EU until late 2027 We are also pleased to have been awarded very significant non-dilutive funding from BARDA and CARB-X to support the development of novel first-in-class antifungals and antibacterials within our R&D portfolio we laid the foundation for future growth by commencing a phase 3 study in invasive yeast infections with our potential next lead product the broad-spectrum antifungal fosmanogepix we aim to continue both progressing our current R&D assets and expanding our portfolio through targeted in-licensing and acquisition of innovative addressing unmet medical needs in the treatment of severe fungal and bacterial diseases.” the commercial performance of Cresemba triggered several milestone payments to Basilea in 2024 Portfolio key highlights 2024 and outlook 2025 Cresemba® (isavuconazole): Indications expanded to pediatric patients Zevtera® (ceftobiprole): US approval and commercialization progress; Chinese NRDL inclusion Clinical and preclinical pipeline: Substantial progress made and significant funding secured This press release can be downloaded from www.basilea.com announced today that it has entered into an exclusive distribution and license agreement with Innoviva Specialty Therapeutics for the commercialization of Basilea’s hospital anti-MRSA antibiotic Zevtera® (ceftobiprole) in the United States (US) Innoviva Specialty Therapeutics is a US-based biopharmaceutical company with an established hospital sales force and a core competence in commercializing anti-infective medicines stated: “We are very pleased with our collaboration with Innoviva Specialty Therapeutics for the commercialization of Zevtera in the US focused and capable partner that shares our vision and ambitions for Zevtera in the US They also have recent experience of launching a hospital antibiotic in the US We are looking forward to working with Innoviva Specialty Therapeutics towards a successful launch and bringing Zevtera to patients in need in the US.” Zevtera will become an important asset in our company’s portfolio allowing us to advance our strategy of providing differentiated therapies in infectious disease and critical care,” said Pavel Raifeld “There is a significant medical need for treatments targeting complicated Staphylococcus aureus infections particularly Staphylococcus aureus bacteremia We are therefore excited to bring this important new medicine to patients who are suffering from these severe infections.” Basilea will receive a USD 4 million upfront payment and tiered royalties on net sales in the high-teens to mid-twenties percentage range Basilea will be eligible to receive sales milestones of up to USD 223 million Innoviva Specialty Therapeutics will purchase its demand of Zevtera drug product from Basilea and Gram-negative bacteria.1 In several countries in Europe and beyond and for the treatment of community-acquired bacterial pneumonia (CABP) Basilea has entered into license and distribution agreements covering more than 80 countries Zevtera is indicated for the treatment of adult patients with Staphylococcus aureus bloodstream infections (bacteremia) (SAB) and adult patients with acute bacterial skin and skin structure infections (ABSSSI) and for adult and pediatric patients (3 months to less than 18 years old) with community-acquired bacterial pneumonia (CABP).2 Basilea’s ceftobiprole phase 3 program is funded in part with federal funds from the US Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response (ASPR); Biomedical Advanced Research and Development Authority (BARDA) Basilea has been awarded approximately USD 112 million or approximately 75 percent of the costs related to the Staphylococcus aureus bacteremia (SAB) and acute bacterial skin and skin structure infections (ABSSSI) phase 3 studies regulatory activities and non-clinical work Innoviva is a diversified holding company with a core royalties portfolio a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”) and a portfolio of strategic investments in healthcare assets Innoviva’s other innovative healthcare assets include infectious disease and critical care assets stemming from acquisitions of Entasis Therapeutics including XACDURO® (sulbactam for injection; durlobactam for injection) co-packaged for intravenous use approved for the treatment of adults with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter baumannii-calcoaceticus complex and the investigational zoliflodacin currently being developed for the treatment of uncomplicated gonorrhea approved to increase blood pressure in adults with septic or other distributive shock and XERAVA® (eravacycline) for the treatment of complicated intra-abdominal infections in adults This ad hoc announcement can be downloaded from www.basilea.com announced today that it was awarded an additional USD 7.3 million from CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) a global non-profit partnership dedicated to supporting the early development of antibacterial products The new funding supports the progression of Basilea’s novel antibiotic candidate BAL2420 (LptA inhibitor) towards the start of first-in-human clinical studies said: "We are very pleased by CARB-X’s continued support for the development of this promising first-in-class drug candidate LptA inhibitors have the potential to address an unmet medical need in the hospital-based treatment of severe infections We look forward to working with CARB-X to bring BAL2420 to patients." BAL2420 belongs to one of the very few novel classes of antibiotics in development which is part of the lipopolysaccharide transport bridge an essential structure in Gram-negative bacteria LptA inhibitors have shown potent and rapid bactericidal activity in vitro and in vivo against Gram-negative bacteria of the Enterobacteriaceae family including strains resistant to beta-lactams and colistin an antibiotic regarded as last-resort therapy.1 Enterobacteriaceae have been highlighted by the World Health Organization (WHO) as priority pathogens against which new antibiotics are urgently needed.2 Basilea has acquired the LptA antibiotics program from Spexis AG in early 2024 Basilea announced that it was awarded an initial CARB-X grant of up to USD 0.9 million to support early preclinical activities The successful completion of these activities resulted in the nomination of BAL2420 as a drug candidate and also led to a final milestone payment from Basilea to Spexis CARB-X’s funding for this project is provided in part with federal funds from the US Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority; Antibacterials branch; under agreement number 75A50122C00028; and by awards from Wellcome (WT224842) and Germany’s Federal Ministry of Education and Research (BMBF) The content of this press release is solely the responsibility of the authors and does not necessarily represent the official views of CARB-X or any of its funders This ad hoc announcement release can be downloaded from www.basilea.com reported today that the sales in 2024 of the antifungal Cresemba® (isavuconazole) and the antibiotic Zevtera® (ceftobiprole) exceeded thresholds triggering sales milestone payments from distribution partners to Basilea in the total amount of approximately CHF 2.2 million this comprises a milestone payment for sales in Canada as well as the first sales milestone payment for the Middle East and North Africa (MENA) region this reflects a milestone payment in Europe said: “We are very pleased with the commercial progress of our two commercialized brands in Canada Their continued growth confirms that Cresemba and Zevtera are serving significant medical needs around the world.” Basilea’s commercial partnerships cover well over 100 countries worldwide Cresemba was marketed in more than 70 countries while Zevtera was marketed in 20 countries Cresemba is approved for use in adults and pediatrics from 1 year up to 18 years for the treatment of invasive aspergillosis and invasive mucormycosis.2 In countries of the MENA region it is indicated in adults for the treatment of invasive aspergillosis and for the treatment of mucormycosis in patients for whom amphotericin B is inappropriate Isavuconazole is also approved in the United States (US),3 the EU4 and several additional countries in Europe and beyond About Zevtera® (ceftobiprole medocaril sodium) and Gram-negative bacteria.6 In several countries in Europe the brand is approved as Zevtera® and Mabelio® for the treatment of adult patients with hospital-acquired bacterial pneumonia (HABP) and for the treatment of community-acquired bacterial pneumonia (CABP).6 Zevtera is also approved in the United States7 This press release can be downloaded from www.basilea.com Archive Architecture a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial or fungal infections announced today that the US Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for the antibiotic ceftobiprole which was submitted to the FDA on August 3rd this year Basilea is seeking approval for treating patients in three indications: Staphylococcus aureus bacteremia (SAB) acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP) as the Prescription Drug User Fee Act (PDUFA) goal date The PDUFA goal date indicates the date for the FDA to complete its review of the NDA which is supported by clinical efficacy and safety data from the phase 3 studies ERADICATE (SAB),1 TARGET (ABSSSI),2 and a phase 3 study in CABP.3 The ERADICATE study was the largest double-blind randomized registrational study conducted for a new antibiotic treatment in SAB said: “We are pleased with the FDA's acceptance of our New Drug Application which is another important step towards bringing ceftobiprole to patients with severe bacterial infections in the US as there is a high medical need for new antibiotic treatment options We look forward to working closely with the FDA throughout their review process.” Ceftobiprole has been designated a Qualified Infectious Disease Product (QIDP) under the US Generate Antibiotics Incentives Now (GAIN) Act; hence ceftobiprole would be eligible to receive ten years of market exclusivity in the US from the date of approval Basilea is planning to commercialize ceftobiprole in the US through a partner and intends to enter into such a partnership prior to the PDUFA goal date Basilea has been awarded approximately USD 112 million or approximately 75 percent of the costs related to the SAB and ABSSSI phase 3 studies with rapid bactericidal activity against a wide range of Gram-positive bacteria such as Staphylococcus aureus and Gram-negative bacteria.4 The brand is currently approved and marketed as Zevtera® and Mabelio® in several countries in Europe and beyond for the treatment of adult patients with hospital-acquired bacterial pneumonia (HABP) Ceftobiprole is currently not approved or partnered in the US This ad hoc announcement can be downloaded from www.basilea.com These two housing blocks are located on the edge of the historic center of Allschwil in Switzerland The project design avoids the usual scheme used in detached houses and hence the dwellings have been grouped in two compact volumes that form an angle of almost ninety degrees and adapt to the topography of the slightly sloping site This layout leaves a generous communal space (instead of the usual private gardens) in which the position of the existing trees has been respected The volume facing east-west accommodates five units with a floor area of 135 square meters each whereas the north-south one contains four dwellings of 158 square meters In each of the houses the domestic space is articulated by a double-height courtyard measuring 15 square meters glazed on three sides and with an operable glass roof These voids bask in natural light and help to improve the thermal behavior of the interior in contrast with the closed appearance of the volumes from the outside Energy is saved thanks to a mechanism that opens and closes the specially designed glass rooftops over the courtyards with a pneumatic system thereby adapting to the changing weather conditions: in summer the rooftops can be opened to cool the interior and in winter they are closed to retain heat This system is enhanced by the building’s thermal inertia with walls of concrete or stone combined with the facade enclosures consisting of prefabricated elements of rockwool to optimize thermal insulation and which are clad in fir tree battens varnished in different hues of brown The need to meet a series of sustainability standards led to the use of vacuum tube collectors to make the most of the solar energy for heating and hot water as well as the extraction of the residual energy of the vitiated air and the placing of an earth grid to preheat or cool fresh air by approximately two or three degrees centigrades These systems are rounded off with a gas-fired unit to generate heat whenever necessary and which is located in the basement of one of the two housing blocks The construction of the buildings mixes solid elements in the slabs and load-bearing walls, and light ones on the facades, the partitions of the bathrooms and the courtyard enclosures. The interior distribution, based on light partitions, endows the dwellings with a great flexibility... [+] Wohnstadt Bau und Verwaltungsgenossenschaft there arent any match using your search terms global biopharmaceutical company Actelion Pharmaceuticals opened a new Business Center in Allschwil Winterhalter Stahlbau; Peters Schüßler Sperr Ingenieurbüro für Bauwesen 7,610m² (plot); 3,190m² (floor area) 104,500m³ (65,900m³ above ground and 37,600m³ underground) global biopharmaceutical company Actelion Pharmaceuticals opened a new Business Center in Allschwil municipality near Basel The project is a building designed on the theme of communication and openness The Actelion Business Center was designed by Herzog & de Meuron Construction of the building was started in August 2007 and completed in December 2010 at a cost of CHF130m ($147.5m) The building has a gross floor area of 27,470m² and offers workspace for 350 employees The company also plans to establish a research and development building in Bachgraben area in Allschwil The facility has an auditorium with a seating capacity for 120 people a 230 people capacity restaurant and 150 car parking spaces The 80m x 80m x 21m building has six upper floors and two basement levels The building has a total volume of 104,500m³ The upper floors are cantilevered by stacking them atop of each other with open Open steel construction allowed the different blocks to jut out in different directions and have different layouts All the floor modules meet at four points that connect the beams of the offices Strict regularity is maintained in these corner points for functionality These core zones have staircases and elevators that provide access to the entire building The access points provide a natural communication-oriented atmosphere to employees The open plan provides light-filled interiors The room modules allow flexible usage of space and can be configured to single office units or offices for two people or manageable open plan offices Ceilings and floors are laid with building installations such as pipes and ducts to create continuous openness Reception area is located at the central point of the hall The four open side wings house the auditorium conference rooms and a variable open space for events The cantilevering floors are made of five to seven prismatic building blocks Each floor is different from the lower floors and has an individual structure The structure that bears the building load is made up of about 3.8km-long steel frames Floor plans were created with about 400m tall trusses and different angular inclinations The steel frame is divided into different sections based on the individual sections of the offices All the linear offices have a varied façade due to the frame sections About 2,500t of steel was processed to create the framework The steel bars are shaped as ‘X’ ‘K’ or straight depending on the static requirements The steel is painted white and plastered for protection against fire The white colour also emphasises the visual identity of the building The four internal staircases required about 100t of steel and another 100t for a spatially disposed structure The building also has 700t of composite beams as secondary support structures the building has several sustainable features such as triple glazed glass windows The building uses a combination of natural gas electrical and renewable energy to meet the cooling and heating demands The design is targeted at conserving the resources and reducing carbon emissions The solid ceilings are thermally activated and all the offices feature separate controllable heat distribution equipment Photovoltaic cells are arranged for partially generating electricity The floor-to-ceiling windows are made of triple-glazed glass to allow maximum natural light into the building It creates transparency to the building and allows eye communication from upwards The 15,020m² of façade area also features sun protection louvres The building is made self-shading by inclining the exposed façade surfaces of the upper floors to downwards The shady lower surfaces are also inclined upwards The building has been landscaped with a mix of horsetail and ivy plantations around the entrance ferns and low-growing Anthurias and palms reach out to the exteriors to reduce the boundary differences The unplanted gravel areas will be landscaped with stonecrops stacked areas of the roofs are landscaped with prairie grass which changes their colour as per the seasons Plant substrates are grown on the other rooftops Give your business an edge with our leading industry insights View all newsletters from across the GlobalData Media network Input your search keywords and press Enter His love affair with cannabinoids started when he suggested CBD to a family member to help with an illness He is passionate about reform as a means to address social inequity and injustice You must be logged in to post a comment Sign up for our newsletter and get the best of our articles delivered to your inbox LEAFIE is a registered trademark of LEAFIE LIMITED.  Join team leafie to stay up to date with all our content We understand that excessive adverts are annoying Without the small amount of revenue these adverts generate Please consider disabling your AdBlocker for leafie to support our work The "Switzerland Innovation Park (SIP) Basel Area Main Campus" is located in the "Life Science" area of the Baselink site in Allschwil The first stage will be allocated to the Urban & Mixed-use investment group the investment decision had already been made in 2021 The transfer took place on January 1 - after completion and reaching an occupancy rate of over 70% The tenants of the office and laboratory building include the Swiss Innovation Park Basel Area the biopharmaceutical company Basilea and the Department of Biomedical Engineering at the University of Basel the SIP Main Campus comprises over 50,000 sqm of leasable space The Main Campus is in turn part of the Baselink site which is located in the Bachgraben in the northeast of the municipality of Allschwil A major life science cluster is already located next to the site The building has LEED Gold certification and is heated fossil-free with 100% geothermal probes The plans for the Main Campus were drawn up by Herzog & de Meuron The Pensimo investment foundation Turidomus has already secured the purchase of the second stage for the Proreal investment group The transfer of ownership of this second part is scheduled to take place in 2024 The area of the Main Campus of the Switzerland Innovation Park Basel Area the innovation park in Allschwil will grow in stages from its current 50,000 m2 to around 115,000 m2 This will make the Main Campus of the Switzerland Innovation Park Basel Area the largest life sciences-focused area of an innovation park in Switzerland The private investor Senn Resources AG is investing around 350 million Swiss francs in the four new buildings that will form part of the Main Campus site which will be constructed in the coming years and integrated into the Switzerland Innovation Park Basel Area in Allschwil will form the Main Campus site together with the existing main building Investor and developer Senn Resources AG is responsible for the realization Gallen-based company already developed and realized the Main Campus main building which was opened by Federal Councillor Guy Parmelin a year ago three of the four new buildings are also being designed by Herzog & de Meuron The radically sustainable HORTUS office building is already under construction (move in 2025) The laboratory and office hybrid buildings ALL (2026) and CLOUD (2028) are in the planning stage Senn is building the public-oriented HOPE building which was developed together with Swiss TPH The expansion of the Main Campus is being carried out in cooperation with Senn Resources AG and the Switzerland Innovation Park Basel Area "It is extremely gratifying that the partnership of a public and private institution is enabling the establishment of an innovation district of this size," says Raymond Cron Managing Director of the national umbrella organization Switzerland Innovation "This not only further enhances the importance of Basel as a life sciences location but also of the Switzerland-wide network of Switzerland Innovation's six parks." the Main Campus of the Switzerland Innovation Park Basel Area will be more than twice as large as it is today and offer significantly more workspaces The innovation park will grow from the 50,000 m2 of usable space currently offered by the Main Campus to around 115,000 m2 This will make Allschwil by far the largest area of a Swiss innovation park dedicated to life sciences CEO of Switzerland Innovation Park Basel Area says: "I am very pleased that we were able to build the innovation park for the benefit of the entire region thanks to the support of the cantons of Basel-Landschaft Basel-Stadt and Jura and that we can now realize this expansion without additional cantonal funding a private partner is making a major contribution to attracting innovative companies to the region and supporting the objectives of Switzerland Innovation." With the US pharmaceutical company Johnson & Johnson moving in the main building is almost fully occupied just one year after opening The other sites in the Switzerland Innovation Park Basel Area are also thriving: the Novartis Campus site has already completed its third expansion phase The Jura site has also already been extended by one floor Occupancy is steadily increasing and only a few offices are still available Source: www.baselarea.swiss ics-Datei {{ video.tag }} {{ video.publishDateTime | date('DD.MM.YYYY') }} Mannschaft des FCB in den eigenen Kalender importieren.  Zum Kalender-Abo FCB-Mitgliedschaft beantragen oder verschenken und Vorteile erfahren Zur Anmeldung Fanshop- und Ticket-Aktionen direkt im Postfach Zur Anmeldung Zum Helpdesk The digital health company Medgate Group is moving into the Alba Haus in the BaseLink area of the municipality of Allschwil (BL) in late summer 2024 An area of 1,443 square meters will accommodate 100 workstations Medgate has a total of 140 employees in the Basel area who work in flexible working models; they will share the new offices The Alba Haus is a 40-metre-high office building designed by architects Herzog & de Meuron The first floor will be open to the public and will serve as a meeting point for users Medgate hopes that this will give them the opportunity to discuss their innovation process with established companies The company also sees a further advantage in the connection between Alba Haus and the life sciences and biotech cluster on the BaseLink site "As an innovative and highly networked company the new quarter being created in the Bachgraben area in Allschwil offers us an ideal environment in which to drive forward our growth strategy," says Andy Fischer Another tenant in the office building is Vebego Schweiz Holding, which will also be responsible for facility management. (ah) Three years after the groundbreaking ceremony the Main Campus of the Switzerland Innovation Park Basel Area was opened on schedule a few days ago Among the 200 or so guests at the official opening ceremony in Allschwil (BL) were Federal Councillor Guy Parmelin and members of the governments of the three sponsoring cantons of Basel-Landschaft which calls itself the most modern in Switzerland About 70% of the space has been leased to 38 companies and institutions but also large companies such as Johnson & Johnson and Basilea "The Basel Area Life Sciences Cluster is not only of enormous importance to the Swiss economy but also occupies a leading position in Europe and worldwide," said Federal Councillor Guy Parmelin in his speech at the official opening The developer of the 50,000 sqm Main Campus is Senn Resources AG with the remaining space designated for offices Approximately 2,000 people will be able to work in the building The heart of the Main Campus is the landscaped courtyard where recreation and dining facilities are available The Main Campus stands in the middle of the Life Sciences Mile in Bachgraben in close proximity to neighbors such as the Swiss Tropical and Public Health Institute Abbott and Idorsia.Groundbreaking for the five-story complex took place in September 2019 Project developer and investor Senn is planning two further new buildings at the Baselink life science hub in Allschwil with completion scheduled for 2026 and 2027 The ALL building has been designed as a sustainable office and laboratory building by Herzog & de Meuron. It is based on the findings from the development of the Main Campus and the sustainable office building Hortus and is "the perfect synthesis of these two buildings - a thoroughly sustainable building that is also suitable for laboratories" offers around 20,000 square meters of flexible office and laboratory space Senn developed the new 10,000 square meter HOPE ("House of Partnership and Engagement") building designed by the Basel office Felippi Wyssen together with the Swiss Tropical and Public Health Institute Swiss TPH It consists of two buildings connected by transparent bridges and is intended to be a place of encounter and exchange Swiss TPH has already secured the top floor as the anchor tenant and four further office floors and the first floor will be rented out for public-oriented uses "These two projects will close the escape along Hegenheimermattweg by 2027 This will also bring Allschwil and the city of Basel even closer together," says Johannes Eisenhut Senn has already implemented several major projects on the 75,000 m² Baselink site the company has developed the Switzerland Innovation Park Basel Area Main Campus as well as the Hortus office building currently under construction Rolf Müller ist kein Unbekannter. Sein Wohnhaus an der Dornacherstrasse haben wir an dieser Stelle zum brutalistischen Meisterwerk erklärt Dennoch ist und bleibt das Werk des 1936 in Luzern geborenen Architekten unterbewertet Ein Einfamilienhaus in Allschwil aus dem Jahre 1961 beweist erneut seine Qualitäten – indem es radikal umgebaut und überformt wurde Featuring Buchner Bründler Architekten würde man im Hiphopjargon sagen Wohnhaus in Allschwil von Buchner Bründler und Rolf Müller © Daisuke Hirabayashi Eternithaus lässt grüssenAuf halbem Weg nach Schönenbuch liegt das Einfamilienhausquartier am südwestlichen Rand Allschwils Hier hat Rolf Müller Anfang der 1960er-Jahre ein zweigeschossiges Wohnhaus erbaut das Zusammenspiel zwischen gestrichenem Mauerwerk und Beton die roten Fensterrahmen und die Metallgeländer mit feinem Drahtgitter als Füllung zeugen vom Optimismus der damaligen Zeit Der beschwingte Geist von Paul Baumgartens “Eternithaus” der Interbau 1957 in Berlin klingt an Wenige Jahre nach Fertigstellung wurde der Bau um einen zweigeschossigen Wohnbereich erweitert Mit der Umnutzung und Erweiterung der Garage kamen weitere Anbauten hinzu “Diese Interventionen verunklärten den Baukörper räumlich und architektonisch beschreiben Buchner Bründler den vorgefundenen Zustand des Hauses Umbau in Schwarz-Weiss-GrünDie Architekten wollten mit ihrer Intervention “die Schnittstellen klären” und der Architektur ihre ursprüngliche Konsistenz zurückgeben Dabei ist das Farb- und Materialkonzept von entscheidender Bedeutung: Schwarz-Weiss-Grün Die neuen Wandflächen wurden mit einer tiefschwarzen Holzschalung aus Seekiefer belegt Die neuen Abdeckungen in Bad und Küche sind betoniert Das Elternschlafzimmer wurde in die ehemalige Garage verlegt wobei sämtliche Oberflächen schwarz sind und die Raumhöhe lediglich 2.10 m beträgt was den räumlichen Bezug in den Garten stärkt Programmatisch wurde ausserdem ein zusätzliches Gästezimmer realisiert In leicht japonisierender Manier verfügt es über eine kreisrunde Öffnung Kasimir Malewitsch) und ein grüner Kreis zieren als Wandmalerei die Seitenwand des überhohen Wohnraums Verschränkung von Alt und NeuOb die Strategie der konsequenten Verschränkung Die neuen architektonischen Elemente führen einen selbstbewussten Dialog (oder eher eine angeregte Diskussion?) mit dem Bestand Buchner Bründler geht es nicht um ein lehrbuchhaftes Rekonstruieren oder gar Inszenieren der ursprünglichen Architektur sie haben den Bestand mit gezielten Eingriffen und prägnanten Materialien formal und räumlich radikalisiert “Die Addition der Bestandteile komplettiert das eine Ganze und ist nicht eine Gegenüberstellung divergierender Themen sagte Andreas Bründler in einem Interview vor über zehn Jahren In Allschwil wurden die Qualitäten den Architektur von Rolf Müller eindrücklich freigelegt – und fulminant ins neue Jahrtausend katapultiert Literatur:Architekturdialoge: Positionen – Konzepte – Visionen © ARCHITEKTUR BASEL | IMPRESSUM | ÜBER UNS | NEWSLETTER The BaseLink site in Allschwil is set to become "a new life science focal point" according to St.Gallen-based real estate company Senn As a central component of the site development Senn is realizing the Grid Campus of Collaboration with the architectural firm Herzog & de Meuron The Swizerland Innovation Park Basel Area will relocate its headquarters to the building and companies and institutions of various sizes will also settle here research institutions and departments of major international corporations active in the healthcare and technology sectors the real estate company announced that the listed Basilea Pharmaceutical Ltd and the University of Basel with its Department of Biomedical Engineering and the Innovation Office will move into the grid The department will occupy a net area of around 3,500 square metres in the grid for research and teaching and will set up workplaces for 150 employees About 1,700 sqm will be developed as technical research space with laboratories workshops and for the technical infrastructure 300 sqm are planned for lectures and seminars Another 1,500 square meters will be used for offices The Innovation Office of the University of Basel will move into offices in the "Innovation Garage" which is located on the ground floor of the Parkhaus West in the immediate vicinity of the grid The Innovation Garage was inspired by the innovative power of "garage companies" and designed as a low-threshold space On 500 sqm there is an event room and collaboration offices The Hortus beer garden is located right next to the parking garage The biotech company Basilea Pharmaceutica will move its headquarters to the Grid in mid-2022 and consolidate various locations in Basel there. According to Senn, Basilea wants to benefit from the proximity to innovative start-ups, academic institutions and other biotech companies. Basilea recently sold its main site at Grenzacherstrasse in Basel as part of a sale and leaseback transaction. The landowner of the BaseLink site at Bachgraben in Allschwil is the Bürgerspital Basel Senn is the building leaseholder for construction sites B1-B4 (Grid) and is also significantly involved in the development of other plots premises are being created for companies and institutions from the life science and biotech sectors The Baselink site in the Bachgraben area of Allschwil comprises a total of 16 construction sites; companies and institutions from the life science sector in particular are to settle here 5,000 to 8,000 jobs will be created on more than 100,000 square meters of floor space Idorsia and Polyphor have already settled on the Baselink site As the real estate developer Senn announces it has acquired the building plots C in building law these offer a lot of potential for further development of the site Managing director Johannes Senn says they are currently in the process of test planning to meet the high demand for laboratory space the architects Felippi Wyssen are realizing a center for patient-oriented research